ReviewFrontiers in microbiology2019
Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Effectiveness of switching regimen in people living with HIV and persistent low-level viraemia in the modern antiretroviral treatment era.HIV medicine · 2026Article
- 5' leader defects drive persistent HIV-1 viremia on long-term ART.Nature communications · 2026Article
- Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab.The Journal of infectious diseases · 2026Article
- Proviruses in CD4Science translational medicine · 2025Article
- HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- HIV-1 testing in the context of expanding PrEP modalities.Journal of the International AIDS Society · 2025Article
- A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era.Current HIV/AIDS reports · 2025Review
- Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk.The Journal of infectious diseases · 2025Article
- Expression of HIV from a 1-LTR circular DNA in the absence of integration.Retrovirology · 2025Article
- The heart of the matter: modeling HIV-associated cardiovascular comorbidities in nonhuman primate models.Frontiers in cellular and infection microbiology · 2025Review
- B/F/TAF forgiveness to non-adherence.Sexually transmitted infections · 2024Article
- Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence.Sexually transmitted infections · 2024Article
- Article
- Low Level Viremia Is Associated With Serious non-AIDS Events in People With HIV.Open forum infectious diseases · 2024Article
- Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen.Viruses · 2024Observational
- Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.Frontiers in immunology · 2024Article
- Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.Current HIV/AIDS reports · 2023Review
- Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia.The Journal of clinical investigation · 2023Article
- Plasma IL-33 levels and immune activation in HIV-TB coinfection: a cross-sectional study in Yaoundé, Cameroon.The Pan African medical journal · 2023Article
- HIV Virologic Failure among Patients with Persistent Low-Level Viremia in Nairobi, Kenya: It Is Time to Review the >1000 Virologic Failure Threshold.BioMed research international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-1 viremia persists at low-levels despite clinically effective antiretroviral therapy (ART). Here we review new methods to quantify and characterize persistent viremia at the single genome level, and discuss the mechanisms of persistence including clonal expansion of infected cells and tissue origins of viremia. A deeper understanding of how viremia persists on ART is critically important to the design of therapies to eliminate viremia and achieve a functional cure for HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.